Literature DB >> 26590131

Frequency of the moyamoya-related RNF213 p.Arg4810Lys variant in 1,516 Korean individuals.

Mi-Ae Jang1, Sue Shin2, Jong Hyun Yoon3, Chang-Seok Ki4.   

Abstract

BACKGROUND: Moyamoya disease (MMD) is a progressive steno-occlusive vasculopathy that involves large intracranial arteries accompanied by abnormal collateral vessels. Recently, RNF213 was identified as a susceptibility gene for MMD and p.Arg4810Lys (rs112735431) is the most common variant in East Asian MMD patients. Interestingly, many studies have reported that a certain proportion of the general population in Japan, Korea, and China also has this variant. In this study, we investigated the frequency of this variant and estimated an odds ratio of MMD using two different Korean populations.
METHODS: A total of 1,516 anonymous DNA samples, 799 from an umbilical cord blood bank and 717 from routine health-checked adults, were genotyped using targeted Sanger sequencing.
RESULTS: The p.Arg4810Lys variant was detected at genotype frequencies of 2.25% (18/799; 95% confidence interval (CI), 1.43-3.53%) in cord blood samples and 2.65% (19/717; 95% CI, 1.70-4.10%) in adult samples, respectively. This variant showed a strong association with MMD (P < 0.001), giving an odds ratio of 162.7 (95% CI, 65.5-403.9) and 137.8 (95% CI, 55.8-339.9) based on the cord blood and adults samples, respectively.
CONCLUSIONS: These results confirm that the RNF213 p.Arg4810Lys variant is not uncommon in the general Korean population and provide reference data for the association of this variant and MMD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26590131      PMCID: PMC4654917          DOI: 10.1186/s12881-015-0252-4

Source DB:  PubMed          Journal:  BMC Med Genet        ISSN: 1471-2350            Impact factor:   2.103


Background

Moyamoya disease (MMD; OMIM 607151) is a rare progressive steno-occlusive vasculopathy that involves intracranial arteries accompanied by abnormal collateral vessels [1]. The annual incidence of MMD is estimated to be 0.35–0.94 per 100,000 person-years in Japan [1, 2], and about one-tenth of that in Europe [3]. In Korea, the annual incidence steadily increased from 1.7 to 2.3 per 100,000 person-years from 2007 to 2011 [4]. Recently, Kamada et al. identified that RNF213 as a susceptibility gene for MMD, and p.Arg4810Lys (rs112735431) as a founder variant common in East Asian MMD patients [5]. In affected Asian families, Liu et al. showed that the RNF213 p.Arg4810Lys variant segregated with the disease and demonstrated a predominantly autosomal dominant inheritance pattern with reduced penetrance [6]. Interestingly, the RNF213 p.Arg4810Lys variant has been found in general populations and the frequency has been estimated to be 0.9–2.7 % [6-8]. Considering the frequency (23.1–90.1 %) of the p.Arg4810Lys variant in MMD, a strong association of this variant and MMD has been suggested, giving an odds ratio of 112–236 [6-8]. In the Korean population, the frequency of the p.Arg4810Lys has been estimated to be 2.69–2.72 % [6, 8]. However, because of the limited numbers of control subjects used in previous studies, further validation of the frequency in a large Korean population is necessary. Therefore, we investigated the frequency of the RNF213 p.Arg4810Lys variant in two Korean populations.

Methods

Subjects

A total of 1,516 anonymous DNA samples were included in this study. Among them, 799 DNAs were obtained from a public umbilical cord blood bank (Seoul Metropolitan Public Cord Blood Bank, Korea) and the remaining 717 DNAs from adult health-examinees were acquired from a hospital-based biobank. All samples were collected from unrelated Koreans who provided informed consent, and the study protocol was approved by the Institutional Review Boards of Seoul National University Boramae Hospital and Samsung Medical Center.

Genotyping of RNF213 p.Arg4810K Variant

Exon 60 of RNF213 was amplified using a primer set designed by the authors: RNF213-e60-F, 5’-gctgcatcacaggaaatgac-3’ and RNF213-e60-R, 5’-aaggagtgagccgagtttga-3’. The PCR products were sequenced on an ABI 3730xl analyzer (Applied Biosystems, Foster City, CA, USA) using a BigDye Terminator v3.1 Cycle sequencing kit (Applied Biosystems). Obtained sequence was compared with the reference sequence for RNF213 (NM_001256071.1).

Statistical Analysis

To assess the data quality of RNF213 p.Arg4810Lys variant, P-values were calculated by an exact test for Hardy-Weinberg equilibrium [9]. To analyze genotype and allele frequency data, differences between control and disease groups were compared by a χ2 or Fisher’s exact test as appropriate. The calculations were performed with VassarStats (http://vassarstats.net/), and 95 % confidence intervals (CI) were calculated for each value. All P-values were based on two-sided comparisons, and P-values < 0.05 were considered to indicate statistical significance.

Results

Genotype distributions of RNF213 p.Arg4810Lys variant in two different sets were in Hardy-Weinberg equilibrium (P = 1.00). Of the 1,516 samples tested by sequence analysis, 2.44 % (37/1,516; 95 % CI, 1.78–3.35 %) were heterozygous for the p.Arg4810Lys variant (Table 1). In the subgroup analysis, the p.Arg4810Lys variant was detected at genotype frequencies of 2.25 % (18/799; 95 % CI, 1.43–3.53 %) in cord blood samples and 2.65 % (19/717; 95 % CI, 1.70–4.10 %) in adult samples, respectively. The genotype frequency of the p.Arg4810Lys variant allele was similar between groups. No homozygote was detected in our study. Estimated frequencies of the variant allele were 1.13 % (95 % CI, 0.72–1.78 %) in cord blood samples and 1.32 % (95 % CI, 0.85–2.05 %) in adult samples. In comparison with the data on Korean MMD patients from a published study (30/38; minor allele frequency, 39.5 %) [6], the carrier containing the RNF213 p.Arg1480Lys variant showed a strong association with MMD in the Korean population (P < 0.001), giving an odds ratio of 162.7 (95 % CI, 65.5–403.9) and 137.8 (95 % CI, 55.8–339.9) based on the cord blood and adults samples, respectively.
Table 1

Population frequencies of the RNF213 p.Arg4810Lys variant in Asian countries

Populationc.14429G > A genotypeSampleCarrier frequency %MAF % P-valuea Reference
(sample type)Wild-type: G/GHetero-zygous: G/AHomo-zygous: A/Asize(95 % CI)(95 % CI)
Korean (adults) 698 19 0 717 2.65 (1.70–4.10) 1.32 (0.85–2.05) - This study
Korean (cord blood) 781 18 0 799 2.25 (1.43–3.53) 1.13 (0.72–1.78) 0.76 This study
Korean (unknown)286802942.72 (1.38–5.28)1.36 (0.69–2.66)1.00[8]
Korean (unknown)217602232.69 (1.24–5.74)1.35 (0.62–2.91)1.00[6]
Japanese (unknown)1,4373431,4742.51 (1.83–3.44)1.36 (1.00–1.85)0.92[8]
Japanese (unknown)374913842.60 (1.42–4.72)1.43 (0.80–2.54)0.84[6]
Chinese (unknown)582505870.85 (0.36–1.98)0.43 (0.18–1.00)0.02[8]
Chinese (unknown)148201501.33 (0.36–4.73)0.67 (0.18–2.40)0.56[6]

Abbreviations: MAF, minor allele frequency; CI, confidence interval

The results from this study are shown in bold

aKorean (adults) vs other study

Population frequencies of the RNF213 p.Arg4810Lys variant in Asian countries Abbreviations: MAF, minor allele frequency; CI, confidence interval The results from this study are shown in bold aKorean (adults) vs other study

Discussion

Early estimates of the genotype and allele frequencies for RNF213 p.Arg4810Lys have been reported to be 2.69–2.72 % and 1.35–1.36 % in the Korean population [6, 8], but so far no large-scale population studies have been performed. In this study, we confirmed that the genotype and allele frequencies of the variant were 2.25–2.65 % and 1.13–1.32 %, respectively, which are similar to frequencies in previous reports. The observed frequencies of RNF213 p.Arg1480Lys variant have also been reported to be similar in proportion to the frequencies reported for the general Japanese population, but the frequencies in the Chinese population are one-thirds less (Table 1). In the latest report investigating the prevalence of MMD in a Korean population cohort, the total number of patients was 16.1 per 100,000 person-years in 2011 [4], which is a continually growing trend. There are several explanations for the high prevalence of MMD. First, the survey is based on the data from National Health Insurance, which is a nationwide universal insurance system, thus all inpatients and outpatients who were diagnosed with MMD were included. Second, widespread use of non-invasive brain magnetic resonance imaging might increase the detection of asymptomatic MMD in adults. According to data from the Korean Statistical Information Service (http://kosis.kr/; accessed on 17 December 2014), the total population was 51.42 million in 2014. Based on the frequency of carriers in this study, the total number of carriers was estimated to be 1.25 million. Assuming that MMD occurs in one of the 300 carriers with the RNF213 p.Arg1480Lys variant [6, 8, 10], the estimated numbers of Korean patients with MMD attributable to RNF213 p.Arg1480Lys is 4,167. On the basis of the observed prevalence of 16.1 per 100,000 persons, these numbers are the minimum estimates, suggesting that this RNF213 p.Arg4810Lys variant is not the single risk factor for MMD. Other modifying factors, such as other RNF213 rare variants, another genetic factor, or environmental factors, might explain the large gap between the prevalence of carrier of the variant allele and the observed prevalence of MMD.

Conclusions

Our data indicate that the RNF213 p.Arg4810Lys variant for MMD is not uncommon in the general Korean population, showing a frequency similar to that of the Japanese population. To our knowledge, this study represents the largest Korean cohort to be analyzed for RNF213 p.Arg4810Lys, and this report will provide reference data for the association of this variant and MMD.
  10 in total

1.  A genome-wide association study identifies RNF213 as the first Moyamoya disease gene.

Authors:  Fumiaki Kamada; Yoko Aoki; Ayumi Narisawa; Yu Abe; Shoko Komatsuzaki; Atsuo Kikuchi; Junko Kanno; Tetsuya Niihori; Masao Ono; Naoto Ishii; Yuji Owada; Miki Fujimura; Yoichi Mashimo; Yoichi Suzuki; Akira Hata; Shigeru Tsuchiya; Teiji Tominaga; Yoichi Matsubara; Shigeo Kure
Journal:  J Hum Genet       Date:  2010-11-04       Impact factor: 3.172

Review 2.  Moyamoya disease: current concepts and future perspectives.

Authors:  Satoshi Kuroda; Kiyohiro Houkin
Journal:  Lancet Neurol       Date:  2008-11       Impact factor: 44.182

3.  A rare Asian founder polymorphism of Raptor may explain the high prevalence of Moyamoya disease among East Asians and its low prevalence among Caucasians.

Authors:  Wanyang Liu; Hirokuni Hashikata; Kayoko Inoue; Norio Matsuura; Yohei Mineharu; Hatasu Kobayashi; Ken-Ichiro Kikuta; Yasushi Takagi; Toshiaki Hitomi; Boris Krischek; Li-Ping Zou; Fang Fang; Roman Herzig; Jeong-Eun Kim; Hyun-Seung Kang; Chang-Wan Oh; David-Alexandre Tregouet; Nobuo Hashimoto; Akio Koizumi
Journal:  Environ Health Prev Med       Date:  2009-11-19       Impact factor: 3.674

4.  genepop'007: a complete re-implementation of the genepop software for Windows and Linux.

Authors:  François Rousset
Journal:  Mol Ecol Resour       Date:  2008-01       Impact factor: 7.090

5.  Moyamoya disease in Europe, past and present status.

Authors:  Y Yonekawa; N Ogata; Y Kaku; E Taub; H G Imhof
Journal:  Clin Neurol Neurosurg       Date:  1997-10       Impact factor: 1.876

6.  Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease.

Authors:  S Miyatake; N Miyake; H Touho; A Nishimura-Tadaki; Y Kondo; I Okada; Y Tsurusaki; H Doi; H Sakai; H Saitsu; K Shimojima; T Yamamoto; M Higurashi; N Kawahara; H Kawauchi; K Nagasaka; N Okamoto; T Mori; S Koyano; Y Kuroiwa; M Taguri; S Morita; Y Matsubara; S Kure; N Matsumoto
Journal:  Neurology       Date:  2012-02-29       Impact factor: 9.910

7.  Distribution of moyamoya disease susceptibility polymorphism p.R4810K in RNF213 in East and Southeast Asian populations.

Authors:  Wanyang Liu; Toshiaki Hitomi; Hatasu Kobayashi; Kouji H Harada; Akio Koizumi
Journal:  Neurol Med Chir (Tokyo)       Date:  2012       Impact factor: 1.742

8.  Novel epidemiological features of moyamoya disease.

Authors:  T Baba; K Houkin; S Kuroda
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-12-12       Impact factor: 10.154

9.  Incidence, prevalence, and survival of moyamoya disease in Korea: a nationwide, population-based study.

Authors:  Il Min Ahn; Dong-Hyuk Park; Hoo Jae Hann; Kyoung Hoon Kim; Hyun Jung Kim; Hyeong Sik Ahn
Journal:  Stroke       Date:  2014-03-04       Impact factor: 7.914

10.  Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.

Authors:  Wanyang Liu; Daisuke Morito; Seiji Takashima; Yohei Mineharu; Hatasu Kobayashi; Toshiaki Hitomi; Hirokuni Hashikata; Norio Matsuura; Satoru Yamazaki; Atsushi Toyoda; Ken-ichiro Kikuta; Yasushi Takagi; Kouji H Harada; Asao Fujiyama; Roman Herzig; Boris Krischek; Liping Zou; Jeong Eun Kim; Masafumi Kitakaze; Susumu Miyamoto; Kazuhiro Nagata; Nobuo Hashimoto; Akio Koizumi
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

  10 in total
  9 in total

1.  Frequency of RNF213 p.R4810K, a susceptibility variant for moyamoya disease, and health characteristics of carriers in the Japanese population.

Authors:  Yang Cao; Hatasu Kobayashi; Takaaki Morimoto; Risako Kabata; Kouji H Harada; Akio Koizumi
Journal:  Environ Health Prev Med       Date:  2016-06-30       Impact factor: 3.674

Review 2.  Role of Ring Finger Protein 213 in Moyamoya Disease.

Authors:  Yong-Gang Ma; Qian Zhang; Le-Bao Yu; Ji-Zong Zhao
Journal:  Chin Med J (Engl)       Date:  2016-10-20       Impact factor: 2.628

3.  Genetic analysis of RNF213 p.R4810K variant in non-moyamoya intracranial artery stenosis/occlusion disease in a Chinese population.

Authors:  Tong Zhang; Congrong Guo; Xin Liao; Jian Xia; XiaoXiao Wang; Jing Deng; Junxia Yan
Journal:  Environ Health Prev Med       Date:  2017-04-24       Impact factor: 3.674

4.  Significant association of RNF213 p.R4810K, a moyamoya susceptibility variant, with coronary artery disease.

Authors:  Takaaki Morimoto; Yohei Mineharu; Koh Ono; Masahiro Nakatochi; Sahoko Ichihara; Risako Kabata; Yasushi Takagi; Yang Cao; Lanying Zhao; Hatasu Kobayashi; Kouji H Harada; Katsunobu Takenaka; Takeshi Funaki; Mitsuhiro Yokota; Tatsuaki Matsubara; Ken Yamamoto; Hideo Izawa; Takeshi Kimura; Susumu Miyamoto; Akio Koizumi
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

5.  Differing disease phenotypes of Duchenne muscular dystrophy and Moyamoya disease in female siblings of a Korean family.

Authors:  Joonhong Park; Woori Jang; Ji Yoon Han
Journal:  Mol Genet Genomic Med       Date:  2019-07-25       Impact factor: 2.183

Review 6.  Ring Finger Protein 213 in Moyamoya Disease With Pulmonary Arterial Hypertension: A Mini-Review.

Authors:  Yuting Luo; Zhixin Cao; Shaoqing Wu; Xunsha Sun
Journal:  Front Neurol       Date:  2022-03-24       Impact factor: 4.003

7.  RNF213 R4810K Variant in Suspected Unilateral Moyamoya Disease Predicts Contralateral Progression.

Authors:  Taedong Ok; Yo Han Jung; Jinkwon Kim; Sang Kyu Park; Goeun Park; Sujee Lee; Kyung-Yul Lee
Journal:  J Am Heart Assoc       Date:  2022-07-25       Impact factor: 6.106

Review 8.  Mystery(n) Phenotypic Presentation in Europeans: Report of Three Further Novel Missense RNF213 Variants Leading to Severe Syndromic Forms of Moyamoya Angiopathy and Literature Review.

Authors:  Claudia Santoro; Giuseppe Mirone; Mariateresa Zanobio; Giusy Ranucci; Alessandra D'Amico; Domenico Cicala; Maria Iascone; Pia Bernardo; Vincenzo Piccolo; Andrea Ronchi; Giuseppe Limongelli; Marco Carotenuto; Vincenzo Nigro; Giuseppe Cinalli; Giulio Piluso
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

Review 9.  The Genetic Basis of Moyamoya Disease.

Authors:  R Mertens; M Graupera; H Gerhardt; A Bersano; E Tournier-Lasserve; M A Mensah; S Mundlos; P Vajkoczy
Journal:  Transl Stroke Res       Date:  2021-09-16       Impact factor: 6.829

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.